August 11, 2020 6:21 AM EDT

Send to a Friend

Roth Capital analyst Jonathan Aschoff reiterated a Sell rating and $11.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the ...

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Source link